

## Spironolactone

Products on Saskatchewan Formulary<sup>1</sup> and Drug Product Database:<sup>2</sup>

Product Name	Dosage Form	DIN	Mfr
<i>Spironolactone only</i>			
Novo-Spiroton	25 mg tablet	00613215	NOP
Aldactone	25 mg tablet	00028606	PFI
Novo-Spiroton	100 mg tablet	00613223	NOP
Aldactone	100 mg tablet	00285455	PFI
<i>Combination Products (spironolactone/hydrochlorothiazide)</i>			
Novo-Spirozine	25 mg/25 mg tablet	00613231	NOP
Aldactazide	25 mg/25 mg tablet	00180408	PFI
Novo-Spirozine	50 mg/50 mg tablet	00657182	NOP
Aldactazide	50 mg/50 mg tablet	00594377	PFI

Spironolactone is available in bulk powder (10 g) for compounding.<sup>3</sup>

Extemporaneous compounding formulae of oral suspension are available:

5 mg/ml:

<http://www.sickkids.ca/pdfs/Pharmacy/2695-Spironolactone.pdf>

Various concentrations ranging from 1 mg/ml to 25 mg/ml:

<http://www.pharminfotech.co.nz/manual/Formulation/mixtures/spironolactone.html>

### Options:

- Switch to combination product if suitable.
- If one tablet strength is available, use for all doses. For low doses that are not feasibly obtained using 100 mg tablets, compound an oral suspension.
- Compound an oral suspension or make capsules with bulk powder.

### Indications:<sup>4</sup>

- Primary hyperaldosteronism
  - o Alternatives - Eplerenone<sup>5</sup> – theoretical, off-label; amiloride<sup>5-7</sup>
- Edematous states:
  - o Congestive heart failure
    - alternative - eplerenone<sup>8,9</sup>
  - o Cirrhosis of the liver accompanied by edema and/or ascites
    - spironolactone is useful because of high plasma aldosterone levels. Often used in combination with furosemide and possibly metolazone.<sup>10</sup>
    - possible alternative - amiloride<sup>10</sup>
  - o The nephrotic syndrome

- complicated; call with specific information
- Essential hypertension
  - alternative – amiloride, triamterene<sup>11,12</sup>
- Hypokalemia when other measures are considered inappropriate or inadequate
  - alternative - amiloride<sup>8</sup>

Off-label use:

- Acne in adult women<sup>10,13</sup>
  - Alternative - cyproterone acetate

References:

1. Saskatchewan Formulary. Drug Plan and Extended Benefits Branch [homepage on the Internet]. Government of Saskatchewan; [updated 2010 Jul 29; cited 2011 Mar 31]. Available from: <http://formulary.drugplan.health.gov.sk.ca/>
2. Health Canada. Drug Product Database Online Query. Ottawa, ON: Health Canada; [updated 2010 Apr 1; cited 2011 Mar 31]. Available from: <http://webprod.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng>
3. Personal phone communication with Emma, Medisca Representative. 1-800-665-6334. 2011 Mar 29
4. e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2011 [updated 2011 Mar 30; cited 2011 Mar 31]. Aldactone [product monograph]. Available from: <http://www.e-cps.ca>. Also available in paper copy from the publisher.
5. Young WF, Kaplan NM, Rose BD. Treatment of primary aldosteronism. In: UpToDate. Lacroix, A (Ed), UpToDate, Waltham, MA, 2011.
6. DynaMed Editorial Team. Primary hyperaldosteronism. Last updated 2010 Sep 1. Available from DynaMed: <http://www.ebscohost.com/dynamed>. Accessed 2011 Apr 3.
7. Canadian Hypertension Education Program. 2010 CHEP Recommendations for the Management of Hypertension. Ontario: Hypertension Canada; [cited 2011 Apr 3]. Available from: <http://hypertension.ca/chep/wp-ontent/uploads/2010/04/FullRecommendations2010.pdf>
8. Ethier J. Fluid and Electrolyte Disorders: Potassium Disturbances. In: Gray Jean, editor. e-Therapeutics+ [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2010 [updated Sep 2010; cited 2011 Mar 31]. Available from: <http://www.e-therapeutics.ca>. Also available in paper copy from the publisher.
9. Jin M, Jensen B, Regier L. Health Failure – Drug and Dosage Considerations. RxFiles drug comparison charts. 8th ed. Saskatoon, SK: Saskatoon Health Region; 2010. p. 12-7. Available from: [www.RxFiles.ca](http://www.RxFiles.ca). Accessed 2011 Mar 31.
10. Swain MG. Gastrointestinal Disorders: Chronic Liver Diseases. In: Gray Jean, editor. e-Therapeutics+ [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2010 [updated Jul 2009; cited 2011 Mar 31]. Available from: <http://www.e-therapeutics.ca>. Also available in paper copy from the publisher.

11. Jensen B, Regier L.. Oral Antihypertensives – Summary/Guidelines Comparison Chart. RxFiles drug comparison charts. 8th ed. Saskatoon, SK: Saskatoon Health Region; 2010. p. 6-15. Available from: [www.RxFiles.ca](http://www.RxFiles.ca). Accessed 2011 Mar 31
12. Campbell NRC, Gibson PG, Tsuyuki RT. Cardiovascular Disorders:Hypertension In: Gray Jean, editor. e-Therapeutics+ [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2010 [updated Nov 2010; cited 2011 Mar 31]. Available from: <http://www.e-therapeutics.ca>. Also available in paper copy from the publisher.
13. Jin M, Regier L , Jensen B. Acne Pharmacotherapy Comparison Chart. RxFiles drug comparison charts. 8th ed. Saskatoon, SK: Saskatoon Health Region; 2010. p. 18-22. Available from: [www.RxFiles.ca](http://www.RxFiles.ca). Accessed 2011 Mar 31.